Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEPS-EA: Intralesional Steroid Injections to Prevent Refractory Strictures in Patients with Esophageal Atresia
2023-504905-36-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 4 trial of triamcinolone in Esophageal stricture and esophageal atresia (EA), sponsored by Erasmus MC. Primary endpoint: Total number of dilatations within 28-day intervals over 6 months. Planned start Jan 2024; status: authorised.
02
Drugs
triamcinolone
03
Conditions
Esophageal strictureesophageal atresia (EA)
Beyond the preview
Go deeper on 2023-504905-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504905-36-00.